Capecitabine Plus Erlotinib in Gemcitabine-Refractory Advanced Pancreatic Cancer
Matthew H. Kulke(Moffitt Cancer Center), Charles S. Fuchs(University of Southern California), Colleen Lawrence(Brigham and Women's Hospital), David P. Ryan(East Carolina University), Lawrence S. Blaszkowsky(Brigham and Women's Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Andrew X. Zhu(Icahn School of Medicine at Mount Sinai), Peter C. Enzinger(Dana-Farber Cancer Institute), Alona Muzikansky(Johns Hopkins University), Eunice L. Kwak(Harvard University), Jeffrey A. Meyerhardt(CancerCare)
Cited by 167
Related Papers
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
|Hepatology|2018|4.7k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
AASLD guidelines for the treatment of hepatocellular carcinoma
|Hepatology|2017|4.2k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k